Study summary
Two immunotherapies helped about 1 in 3 people with treated adrenal cancer, some for years
33%had their cancer shrink or stay stable for more than 6 months
What was tested
Ipilimumab plus nivolumab in adrenocortical carcinoma that had grown after other treatment, within a national rare-cancer trial.
What they found
- Tumors shrank in 19%; 33% had shrinkage or more than 6 months of stable disease.
- A few people had no growth for more than 4 years.
- Serious liver problems and adrenal insufficiency each occurred in about 10%.
What it means
Immunotherapy helps a minority, sometimes for a long time. Finding who will respond is the next step.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.